Navigation Links
Verenium Completes Amendment to 8% Senior Convertible Notes
Date:7/6/2009

CAMBRIDGE, Mass., July 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM) announced today that the agreement to amend the $29.5 million of outstanding 8% Senior Convertible Notes due April 1, 2012 (the "Notes") entered into and announced on July 1, 2009 is effective as of 8:00 a.m. today. The Company has entered into Convertible Note Amendment Agreements with holders of 87% of the Notes, which is above the required 66.67% necessary to amend the outstanding Notes. Lazard Freres & Co. LLC acted as an advisor for this transaction.

"We are pleased to have been able to work with our 8% noteholders to amended the terms of the notes, removing or modifying several restrictions that limited the Company's financial and operational flexibility," said Carlos A. Riva, President and Chief Executive Officer at Verenium. "This along with the recent news that our joint venture with our partner BP has been selected to enter into the due diligence phase of the DOE Loan Guarantee Program, puts us in a much stronger position as we look toward securing the necessary financing required for our first commercial facility."

In exchange for lowering the conversion price of the Notes from $2.13 to $1.74, the benefits Verenium receives from the amendment include:

  • Modifications providing Verenium with greater flexibility to engage in certain financing and other strategic transactions, including the ability to incur indebtedness or liens and engage in restructuring transactions involving its 5.50% convertible senior notes;
  • Modifications that allow the company to raise capital with less dilution to the existing shareholders; and
  • Clarifications that provide for interest and make-whole payments to be made in shares of our common stock.

'/>"/>
SOURCE Verenium Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Verenium Corporation to Present at the Upcoming Cowen and Company Clean Energy Conference
2. Verenium Advances Its Development Work With Cargill on a New Food-Related Product
3. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
4. Verenium Explores Bacterial Genes Inside Termite Guts to Understand How Wood is Broken Down and Converted to Energy
5. Verenium Corporation to Present at Piper Jaffray Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the First Quarter 2008
7. Verenium Appoints John F. Dee to Board of Directors
8. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
9. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
10. Verenium Corporation to Announce Third Quarter 2008 Financial Results
11. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., Dec. 1 GeoVax Labs, I...n Atlanta-based, biopharmaceutical company develop...uman Immunodeficiency Virus) and other infectious ... Day. ,, "Today is the 21st World AIDS Day and ...ight with the HIV/AIDS pandemic, we remain focused...
(Date:12/1/2009)... A new clinical study presented to the America...ee-dimensional (3-D) automated ultrasound follicle... in vitro fertilization (IVF) cycle is effective a...ent of the follicles. , G... Fertility Center of Chicago has just completed re...
(Date:12/1/2009)... iCardiac now provides services to three out o... Rochester, NY (PRWEB) Decemb...l leader in advanced cardiac core lab services and...maceutical company has selected iCardiac as a pref...ill provide Highly Automated QT(sm) and Dynamic QT...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of the hi... Technologies, a business development and intellec...erging nanotechnology space. The company also pla...a nanotechnology incubator. , ...hael R. Drapp , a 34-year veteran of the high-tech...
Breaking Biology Technology:GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 2GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 3GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 4GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 5GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 6Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4
...Burrill Merchant Banking acted as,exclusive financ...completed,commercial partnering of bilastine with ... agreement, Faes has licensed bilastine rights in ...ment of seasonal allergic,rhinitis., Bilastine is...daily,oral administration. Allergic rhinitis preva...
... N.C., Jan. 9 Quintiles,Transnational Corp. today...Global Central Laboratories and Clinical Developme...their growing business in China., The new consoli...000,square feet of space, is located at Sun Dong A...ious lab site in the Peking Union Medical College,...
...overnment to apply rating system to home DNA tests...resented tests, WASHINGTON, Jan. 9 Should consum...heir personal health through home DNA tests?,Accor...r is: absolutely. "I,agree with scientific opinion... year by DNA testing that reveal potential adverse...
Other Biology Technology:Burrill Merchant Banking Advises Faes Farma on Bilastine Licensing Agreement 2Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility 2Genelex Corporation Defends Consumers' Right to Obtain DNA Information: 2
(Date:11/30/2009)... A team of scientists from The Forsyth Institute,...CDC and the Wadsworth Center, have used state-of-t...tecture of Treponema pallidum, the bacterium which...structure of the bacteria can now be shown in thre...f the pathogen and reveals previously unknown feat...
(Date:11/30/2009)... The Editors of The Journal of Experimental Biol... from Centre National de la Recherche Scientifique...is the winner of this year,s JEB Outstanding Pap...an outstanding achievement and is intended to enco... JEB Editor-in-Chief, and adds that ,we truly app...
(Date:11/30/2009)... A major obstacle to HIV research is the virus,s ...ng that scientists, traditional tools, like the hu...on. Now, a team of researchers writing in BioMed C...e an ingenious assault on this problem by creating...thout being infected with HIV. , George Kassioti...
Breaking Biology News(10 mins):Scientists gain new understanding of disease-causing bacteria 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4A reductionist approach to HIV research 2Swanson Health Products 26apos 3B Vitamin E and Acai Dietary Supplements Pass Quality Control Tests Conducted by ConsumerLab com 56910 1Swanson Health Products 26apos 3B Vitamin E and Acai Dietary Supplements Pass Quality Control Tests Conducted by ConsumerLab com 56910 2Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 1Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 2Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 3Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 4Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 5Cardinal Health Announces Early Tender Results of Debt Tender Offer 56907 6Winner Medicals Shenzhen Subsidiary Obtained High and New Technology Enterprise Certificate 56904 1Winner Medicals Shenzhen Subsidiary Obtained High and New Technology Enterprise Certificate 56904 2Winner Medicals Shenzhen Subsidiary Obtained High and New Technology Enterprise Certificate 56904 3
...in that activates estrogen receptors in breast can...ffects of anti-estrogen tamoxifen treatment, accor...ional Cancer Institute. , Pak 1 is a member of a...s, such as gene expression, cell movement, and cel... presence of this protein may lead to more invasiv...
...hich used to be referred to as Type 1 diabetes, re...ing pancreatic islet beta cells by the body,s immu...the pancreas and are made up of two types of cells... raises the level of glucose (sugar) in the blood,... appears in the May 12 issue of The Journal of Bio...
...sts at Washington University in St. Louis have mad...hway plant cells take to silence unwanted or extra...ve made it possible to see where, and how, the eve...ing is believing, as the old saying goes. ,...ssor of biology in Arts & Sciences and his col...
Other Biology News:Pak1 expression increases tamoxifen resistance in breast cancer patients 2New study reveals signaling pathways required for expansion of pancreas stem cells 2New study reveals signaling pathways required for expansion of pancreas stem cells 3Pathway toward gene silencing described in plants 2Pathway toward gene silencing described in plants 3Pathway toward gene silencing described in plants 4
HRP Protein Marker Detection Pack from New England Biolabs
Mouse Anti-Y14 Monoclonal Antibody, Unconjugated, Clone 4C4 from Abcam
Rabbit Anti-Human JMJD2B Polyclonal Antibody, Unconjugated from ProSci, Inc
Large Volume UltraMount from Lab Vision
Biology Products: